The Food and Drug Administration (FDA) presented the preliminary results of new research on montelukast at the American College of Toxicology meeting recently, describing potential side-effect risks for the oral asthma drug. Montelukast may be leading to mental health conditions and suicide by attaching to multiple brain receptors that are involved in psychiatric functioning, researchers say. According to Reuters, thousands of patients have reported neuropsychiatric episodes, prompting the FDA to launch a comprehensive investigation and …
Read More